FILE PHOTO: The exterior of the European Medicines Agency is seen in Amsterdam, Netherlands, December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo
(Reuters) – The European medicines regulator said on Monday it would hold a meeting this week on the information gathered into whether the AstraZeneca COVID-19 vaccine contributed to thromboembolic events in those inoculated.
While its investigation is ongoing, the European Medicines Agency remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19 outweigh the risks of side effects. (bit.ly/3trmufB)
Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.
After years of material science breakthroughs, a team proved that a rugged, sea-ready composite could…
TAHO, a Venice-based compute startup founded by ex-Meta and Google engineers, raised $3.5 million in…
The 9th Future Investment Initiative in Riyadh spotlighted how AI is rapidly redefining global growth,…
Onward Robotics has appointed Brendon Bielat as Chief Product Officer, strengthening its leadership team as…
Dubai, UAE, 12th December, 2025: The Fédération Internationale de l’Automobile (FIA), the global governing body for motor sport…
FIA President Mohammed Ben Sulayem says new agreement secures the FIA Formula One World Championship’s…